| 摘要 |
PROBLEM TO BE SOLVED: To evade chemotherapy resistance of a tumor to a cell proliferation inhibitor.SOLUTION: This invention relates to a method for combined use for administering simultaneously, individually or sequentially a combination of agents containing a casein kinase 2 phosphorylated inhibitor (called as p 15) and a cell proliferation inhibitor used in cancer chemotherapy. A preferable cell proliferation inhibitor is platinum, taxane, Vinca major L. genus alkaloid, 5-fluorouracil, Doxorubicin, Cyclophosphamide, Etoposide, mitomycin C, imatinib, Iressa and velcade (bortezomib). A synergistic effect between the peptide p 15 and an anticancer compound means that the effective concentration of each cell proliferation inhibitor in the method for combined use is lower by 1-2 figures than an effective concentration corresponding to a cell proliferation inhibitor as a single agent. Resultantly, the combination described in this invention has far lower toxicity than toxicity reported relative to an anticancer cell proliferation inhibitor, and the fact is an important advantage for the use thereof in cancer treatment. Further, sequential administration brings about chemical sensitization by premedication of the peptide p 15 of a tumor unresponsive to the anticancer cell proliferation inhibitor. |
